Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02266004
Other study ID # 20140127
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 12, 2014
Est. completion date June 27, 2018

Study information

Verified date June 2020
Source University of Miami
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the effects of transcranial direct current stimulation (tDCS) in combination with locomotor training in patients with Parkinson's disease (PD) and freezing of gait (FOG).


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date June 27, 2018
Est. primary completion date June 27, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. age 18- 80

2. Parkinson's disease stages 2-3 Hoehn and Yahr.

3. Presence of Freezing of Gait

4. Stable medication regimen

5. Time to complete TUG >12 seconds

Exclusion Criteria:

1. medical condition that would interfere with walking and training for 30 minutes

2. unable to perform timed up and go in the off condition

3. history of seizures

4. implanted deep brain stimulator, pacemaker or any other electronic device.

5. dementia

6. Adults unable to consent, individuals who are not yet adults (infants, children, teenagers) pregnant women, prisoners will not be considered for participation

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcranial Direct Current Stimulation (tDCS)
Anodal tDCS will be applied for the duration of the walking training at 2 milliamps with IOMED Phoresor.
Other:
locomotor training
An individualized dual-task walking program for approximately 30 minutes.

Locations

Country Name City State
United States University of Miami Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Walking Speed walking speed will be measured using sensors during a 90 second walk baseline, 3 weeks
Secondary Change in Motor Scores as Measured by Unified Parkinson's Disease Rating Scale (UPDRS) UPDRS motor score range from 0-56 with higher scores indicating greater impairment. baseline, 3 weeks
Secondary Change in Stride Length Stride length is measured with mobile sensors attached to participant's extremities during the 90 second walk. baseline, 3 weeks
Secondary Change in Postural Sway Postural sway is measured with mobile sensors attached to participant's extremities during the 30 seconds of quiet standing. baseline, 3 weeks
Secondary Change in Timed Up-and-Go (TUG) Time Participants are timed while standing up from a chair, walking around a cone, and returning to their chair. baseline, 3 weeks
Secondary Change in Motor Threshold Transcranial magnetic stimulation is used to measure motor threshold of the primary motor area. The motor threshold was defined as the minimum intensity needed to evoke 5 out 10 motor evoked potentials in the first dorsal interosseous muscle in the hand. baseline, 3 weeks
Secondary Change in Glutamate/Gamma Aminobutyric Acid(GABA) Ratio Glutamate/GABA ratio will be measured with magnetic Resonance Spectroscopy (MRS). baseline, 3 weeks
Secondary Change in Backward Digit Span Digit span is measured by total number of correct digits recited. baseline, 3 weeks
Secondary Change in the Trail Making Test Time Trail making test is measured as the number of seconds required to complete the task, with higher scores indicating greater impairment. baseline, 3 weeks
Secondary Change in the Montreal Cognitive Assessment (MOCA) The MOCA has a total score ranging from 0-30 with a higher score indicating better performance. baseline, 3 weeks
Secondary Change in the Auditory Consonant Trigrams Test (ACT) The ACT has a score from 0-60 with higher score indicating better performance. baseline, 3 weeks
Secondary Change in the Freezing of Gait Questionnaire (FOG-Q) The FOG-Q has a total score ranging from 0-24 with higher scores indicating more incidents of freezing. baseline, 3 weeks
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Completed NCT02874274 - Vaccination Uptake (VAX) in PD N/A
Terminated NCT02924194 - Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease N/A